ProteinLogic has developed the ImmiPrint® diagnostic technology platform, which leverages machine learning to detect unique patterns in soluble immune proteins found in blood and other body fluids. This innovative approach allows for the identification of disease signatures that indicate the presence, stage, and potential treatment responses for various conditions. Clinically validated for ruling out Active Tuberculosis (TB), ImmiPrint® meets the World Health Organization's stringent criteria for diagnostic tests. The company aims to expand its capabilities by validating additional ImmiPrint® signatures for a range of infectious, autoimmune, and inflammatory diseases, thereby enhancing the early diagnosis and management of these conditions.

The technology is built upon the discovery of soluble CD antigens, which are proteins released into the bloodstream that correlate with specific diseases. ProteinLogic's ImmiPrint® technology distinguishes itself by utilizing high-throughput immunoassays to measure multiple immune system proteins simultaneously, rather than focusing on a limited number of biomarkers. This method, combined with advanced pattern recognition software, enables the generation of disease-specific biomarker signatures, facilitating a more efficient and cost-effective diagnostic process. The platform's versatility allows it to be applied across various diseases, offering significant advantages such as high sensitivity and specificity, rapid testing, and the potential to transform clinical diagnostics and biomarker discovery.

United Kingdom

ProteinLogic has developed ImmiPrint®, a novel diagnostic technology platform, based on the detection of non-obvious diagnostic patterns in soluble immune proteins in the blood and other body fluids through machine learning.

ProteinLogic

Company Details